Andrographolide as a potential inhibitor of SARS-CoV-2 main protease: an in silico approach

SARS-CoV-2 virus which caused the global pandemic the Coronavirus Disease- 2019 (COVID-2019) has infected about 1,203,959 patients and brought forth death rate about 64,788 among 206 countries as mentioned by WHO in the month of April 2020. The clinical trials are underway for Remdesivir, an investigational anti-viral drug from Gilead Sciences. Antimalarial drugs such as Chloroquine and Hydroxychloroquine derivatives are being used in emergency cases; however, they are not suitable for patients with conditions like diabetes, hypertension and cardiac issues. The lack of availability of approved treatment for this disease calls forth the scientific community to find novel compounds with the ability to treat it. This paper evaluates the compound Andrographolide from Andrographis paniculata as a potential inhibitor of the main protease of SARS-COV-2 (Mpro) through in silico studies such as molecular docking, target analysis, toxicity prediction and ADME prediction. Andrographolide was docked successfully in the binding site of SARS-CoV-2 Mpro. Computational approaches also predicts this molecule to have good solubility, pharmacodynamics property and target accuracy. This molecule also obeys Lipinski's rule, which makes it a promising compound to pursue further biochemical and cell based assays to explore its potential for use against COVID-19. Communicated by Ramaswamy H. Sarma

Automated summary

The SARS-CoV-2 virus has caused a global pandemic with over 1.2 million confirmed cases and nearly 65,000 deaths, leading to a search for effective treatments. Clinical trials are being conducted on antiviral drugs, but the lack of approved treatments highlights the need for novel compounds. Andrographolide from Andrographis paniculata shows promise as an inhibitor for SARS-CoV-2 main protease, with in silico studies suggesting good solubility, pharmacodynamics properties, and target accuracy.